Literature DB >> 24573570

[Prostate cancer].

T Franiel1, N Eckardt, M Waginger, M Horstmann.   

Abstract

For many clinical issues regarding prostate cancer magnetic resonance imaging (MRI) is gaining increasing importance for prostate diagnostics. The high morphological resolution of T2-weighted sequences is unsurpassed compared to other imaging modalities. It enables not only the detection and localization of prostate cancer but also allows the evaluation of extracapsular extensions. Functional MRI methods, such as diffusion-weighted imaging (DWI), dynamic contrast-enhanced (DCE) MRI and proton magnetic resonance spectroscopy ((1)H-MRS) increase the specificity and to a lesser extent, the sensitivity of diagnostics. In accordance with the interdisciplinary S3 guidelines, prostate MRI is recommended for patients with at least one negative biopsy for cancer detection. According to the guidelines areas suspected of being cancerous should be selectively biopsied in addition to the systematic biopsy. The transmission of findings about the suspected tumor areas according to the structured PI-RADS classification system has proven its worth. The localization and staging of prostate carcinoma is best achieved with the help of MRI and is recommended in the S3 guidelines especially for tumors with a clinical stage cT3/4 or with a Gleason grading system score ≥8. In addition to these applications MRI is mainly used under study conditions for local recurrence or active surveillance.

Entities:  

Mesh:

Year:  2014        PMID: 24573570     DOI: 10.1007/s00117-013-2608-0

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  64 in total

1.  Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging.

Authors:  Stefano Cirillo; Massimo Petracchini; Lorenza Scotti; Teresa Gallo; Annalisa Macera; Maria Cristina Bona; Cinzia Ortega; Pietro Gabriele; Daniele Regge
Journal:  Eur Radiol       Date:  2008-09-30       Impact factor: 5.315

2.  Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results.

Authors:  G J Jager; E T Ruijter; C A van de Kaa; J J de la Rosette; G O Oosterhof; J R Thornbury; S H Ruijs; J O Barentsz
Journal:  Radiology       Date:  1997-06       Impact factor: 11.105

3.  [Histopathologic quality of prostate core biopsy specimens: comparison of an MR-compatible biopsy needle and a ferromagnetic biopsy needle used for ultrasound-guided prostate biopsy].

Authors:  T Franiel; F Fritzsche; A Staack; J Rost; B Hamm; D Beyersdorff
Journal:  Rofo       Date:  2006-08-25

4.  MRI-guided biopsy of the prostate: correlation between the cancer detection rate and the number of previous negative TRUS biopsies.

Authors:  Tahir Durmuş; Uta Reichelt; Alexander Huppertz; Bernd Hamm; Dirk Beyersdorff; Tobias Franiel
Journal:  Diagn Interv Radiol       Date:  2013 Sep-Oct       Impact factor: 2.630

5.  High-b-value diffusion-weighted imaging at 3 T to detect prostate cancer: comparisons between b values of 1,000 and 2,000 s/mm2.

Authors:  Chan Kyo Kim; Byung Kwan Park; Bohyun Kim
Journal:  AJR Am J Roentgenol       Date:  2010-01       Impact factor: 3.959

6.  Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging.

Authors:  K K Yu; J Scheidler; H Hricak; D B Vigneron; C J Zaloudek; R G Males; S J Nelson; P R Carroll; J Kurhanewicz
Journal:  Radiology       Date:  1999-11       Impact factor: 11.105

Review 7.  How good is MRI at detecting and characterising cancer within the prostate?

Authors:  Alexander P S Kirkham; Mark Emberton; Clare Allen
Journal:  Eur Urol       Date:  2006-06-30       Impact factor: 20.096

8.  Comparative sensitivities of functional MRI sequences in detection of local recurrence of prostate carcinoma after radical prostatectomy or external-beam radiotherapy.

Authors:  Catherine Roy; Fatah Foudi; Jeanne Charton; Michel Jung; Hervé Lang; Christian Saussine; Didier Jacqmin
Journal:  AJR Am J Roentgenol       Date:  2013-04       Impact factor: 3.959

Review 9.  Imaging of recurrent prostate cancer.

Authors:  Jurgen J Fütterer
Journal:  Radiol Clin North Am       Date:  2012-10-11       Impact factor: 2.303

10.  ESUR prostate MR guidelines 2012.

Authors:  Jelle O Barentsz; Jonathan Richenberg; Richard Clements; Peter Choyke; Sadhna Verma; Geert Villeirs; Olivier Rouviere; Vibeke Logager; Jurgen J Fütterer
Journal:  Eur Radiol       Date:  2012-02-10       Impact factor: 5.315

View more
  1 in total

Review 1.  [Irreversible electroporation (IRE) : A minimally invasive therapeutic option in prostate cancer].

Authors:  P Wiggermann; K Brünn; W Bäumler
Journal:  Radiologe       Date:  2017-08       Impact factor: 0.635

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.